Logo image of CMPS

COMPASS PATHWAYS PLC (CMPS) Stock Fundamental Analysis

USA - NASDAQ:CMPS - US20451W1018 - ADR

6.52 USD
+0.11 (+1.72%)
Last: 10/17/2025, 5:38:32 PM
6.5262 USD
+0.01 (+0.1%)
After Hours: 10/17/2025, 5:38:32 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CMPS. CMPS was compared to 536 industry peers in the Biotechnology industry. Both the profitability and financial health of CMPS have multiple concerns. CMPS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CMPS had negative earnings in the past year.
CMPS had a negative operating cash flow in the past year.
In the past 5 years CMPS always reported negative net income.
In the past 5 years CMPS always reported negative operating cash flow.
CMPS Yearly Net Income VS EBIT VS OCF VS FCFCMPS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

CMPS has a Return On Assets (-47.22%) which is in line with its industry peers.
CMPS has a Return On Equity of -85.26%. This is comparable to the rest of the industry: CMPS outperforms 50.37% of its industry peers.
Industry RankSector Rank
ROA -47.22%
ROE -85.26%
ROIC N/A
ROA(3y)-53.97%
ROA(5y)-43.08%
ROE(3y)-67.74%
ROE(5y)-51.83%
ROIC(3y)N/A
ROIC(5y)N/A
CMPS Yearly ROA, ROE, ROICCMPS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

CMPS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMPS Yearly Profit, Operating, Gross MarginsCMPS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for CMPS has been increased compared to 1 year ago.
Compared to 5 years ago, CMPS has more shares outstanding
Compared to 1 year ago, CMPS has a worse debt to assets ratio.
CMPS Yearly Shares OutstandingCMPS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CMPS Yearly Total Debt VS Total AssetsCMPS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

CMPS has an Altman-Z score of -1.19. This is a bad value and indicates that CMPS is not financially healthy and even has some risk of bankruptcy.
CMPS's Altman-Z score of -1.19 is in line compared to the rest of the industry. CMPS outperforms 54.85% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that CMPS is not too dependend on debt financing.
CMPS's Debt to Equity ratio of 0.14 is on the low side compared to the rest of the industry. CMPS is outperformed by 65.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z -1.19
ROIC/WACCN/A
WACCN/A
CMPS Yearly LT Debt VS Equity VS FCFCMPS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 8.82 indicates that CMPS has no problem at all paying its short term obligations.
CMPS has a better Current ratio (8.82) than 77.05% of its industry peers.
CMPS has a Quick Ratio of 8.82. This indicates that CMPS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 8.82, CMPS is in the better half of the industry, outperforming 77.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.82
Quick Ratio 8.82
CMPS Yearly Current Assets VS Current LiabilitesCMPS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

CMPS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.29%, which is quite good.
EPS 1Y (TTM)14.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CMPS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.73% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.52%
EPS Next 2Y15.07%
EPS Next 3Y10.76%
EPS Next 5Y5.73%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CMPS Yearly Revenue VS EstimatesCMPS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
CMPS Yearly EPS VS EstimatesCMPS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CMPS. In the last year negative earnings were reported.
Also next year CMPS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMPS Price Earnings VS Forward Price EarningsCMPS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMPS Per share dataCMPS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.07%
EPS Next 3Y10.76%

More info and screens

0

5. Dividend

5.1 Amount

CMPS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COMPASS PATHWAYS PLC

NASDAQ:CMPS (10/17/2025, 5:38:32 PM)

After market: 6.5262 +0.01 (+0.1%)

6.52

+0.11 (+1.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)10-29 2025-10-29
Inst Owners55.61%
Inst Owner Change0%
Ins Owners1.76%
Ins Owner Change-0.09%
Market Cap610.02M
Analysts82.5
Price Target15.2 (133.13%)
Short Float %8.29%
Short Ratio3.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.22%
Min EPS beat(2)6.08%
Max EPS beat(2)20.36%
EPS beat(4)4
Avg EPS beat(4)8.15%
Min EPS beat(4)2.27%
Max EPS beat(4)20.36%
EPS beat(8)4
Avg EPS beat(8)-11.49%
EPS beat(12)7
Avg EPS beat(12)-3.88%
EPS beat(16)10
Avg EPS beat(16)0.19%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.45%
EPS NY rev (1m)0%
EPS NY rev (3m)8.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.75
P/tB 3.75
EV/EBITDA N/A
EPS(TTM)-1.98
EYN/A
EPS(NY)-1.55
Fwd EYN/A
FCF(TTM)-1.59
FCFYN/A
OCF(TTM)-1.59
OCFYN/A
SpS0
BVpS1.74
TBVpS1.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.22%
ROE -85.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.97%
ROA(5y)-43.08%
ROE(3y)-67.74%
ROE(5y)-51.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.82
Quick Ratio 8.82
Altman-Z -1.19
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)69.7%
Cap/Depr(5y)102.12%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.79%
EPS Next Y33.52%
EPS Next 2Y15.07%
EPS Next 3Y10.76%
EPS Next 5Y5.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.92%
EBIT Next 3Y-0.29%
EBIT Next 5Y7.15%
FCF growth 1Y-26.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.1%
OCF growth 3YN/A
OCF growth 5YN/A